Global Shingles Vaccine Market Size & Outlook, 2025-2030
Global shingles vaccine market, 2018-2030 (US$M)
Global shingles vaccine market highlights
- The global shingles vaccine market generated a revenue of USD 4,782.2 million in 2024 and is expected to reach USD 11,261.8 million by 2030.
- The market is expected to grow at a CAGR (2025 - 2030) of 15.7% by 2030.
- In terms of segment, shingrix accounted for a revenue of USD 5,427.3 million in 2024.
- Shingrix is the most lucrative product segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
Global data book summary
| Market revenue in 2024 | USD 4,782.2 million |
| Market revenue in 2030 | USD 11,261.8 million |
| Growth rate | 15.7% (CAGR from 2025 to 2030) |
| Largest segment | Shingrix |
| Fastest growing segment | Shingrix |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Shingrix |
Other key industry trends
- In terms of revenue, the North America accounted for 62.3% of the global shingles vaccine market in 2024.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Shingles Vaccine Market Scope
Shingles Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| GeneOne Life Science | View profile | - | Soeul, Ch'ungch'ong-namdo, South Korea, Asia | https://www.genels.com/index.asp |
| CanSino Biologics Inc Class H | View profile | 1494 | 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, China, People's Republic of, | https://www.cansinotech.com |
| Barinthus Biotherapeutics PLC ADR | View profile | 130 | Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, United Kingdom, OX11 0DF | https://www.barinthusbio.com |
| Green Cross Health Ltd | View profile | - | 602 Great South Road, Ellerslie, Ground Floor, Building B, Millennium Centre, Auckland, NTL, New Zealand, 1051 | https://www.greencrosshealth.co.nz |
| Skye Bioscience Inc Ordinary Shares | View profile | 11 | 11250 El Camino Real, Suite 100, San Diego, CA, United States, 92130 | https://www.skyebioscience.com |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
Global shingles vaccine market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to shingles vaccine market will help companies and investors design strategic landscapes.
Shingrix was the largest segment with a revenue share of 113.49% in 2024. Horizon Databook has segmented the Global shingles vaccine market based on shingrix covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Shingles Vaccine Product Outlook (Revenue, USD Million, 2018-2030)
- Shingrix
- Zostavax
- SkyZoster
- Global Shingles Vaccine Vaccine Type Outlook (Revenue, USD Million, 2018-2030)
- Recombinant vaccines
- Live-attenuated vaccines
- Global Shingles Vaccine End Use Outlook (Revenue, USD Million, 2018-2030)
- Private Healthcare Settings
- Government Healthcare Settings
Reasons to subscribe to Global shingles vaccine market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global shingles vaccine market databook
-
Our clientele includes a mix of shingles vaccine market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global shingles vaccine market , including forecasts for subscribers. This global databook contains high-level insights into Global shingles vaccine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global shingles vaccine market size, by regions, 2018-2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
